MedTrace Logo

Pilot Study for the Early Detection of Chronic Kidney Disease, Non-Dialysis Objective (NDO).

NCT06447038 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2024-06-06

No results posted yet for this study

Summary

Chronic kidney disease (CKD) is a significant public health problem worldwide, affecting more than 10% of the Spanish population. Early detection is considered a top healthcare priority to establish strategies for preventing progression to more advanced stages of the disease and its complications. Additionally, CKD is associated with high comorbidity, poor prognosis, and substantial resource consumption within the healthcare system. In this context, albuminuria may be a more sensitive marker of CKD than reduced glomerular filtration rate (GFR), and it is also considered an indicator of not only renal damage but also \"systemic damage\" (generalized endothelial dysfunction, arterial remodeling, and increased cardiovascular risk) beyond the kidney. Furthermore, the reduction of proteinuria/albuminuria is clearly associated with a slower progression of CKD, making its reduction a therapeutic goal as well. Given this importance, this protocol aims to determine the urine albumin/creatinine ratio in all patients over 18 years old who visit their primary care physician in the province of Burgos, Spain, and require a blood test related to their reason for consultation.

Conditions

  • Chronic Kidney Disease (CKD)

Interventions

DIAGNOSTIC_TEST

albumin creatinine ratio

Albumin creatinine ratio, this test is routinely performed in urine.

Sponsors & Collaborators

  • Hospital Universitario de Burgos

    lead OTHER

Principal Investigators

  • Maria J Izquierdo Ortiz, Doctor · HUBU

  • Emilio J Gonzalez Parra, Doctor · HUBU

  • Sebastian Mas Fontao, Doctor · HUBU

  • Maria Martin Palencia, Doctor · HUBU

  • Didier Sanchez, Doctor · HUBU

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2024-10-31
Completion
2024-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06447038 on ClinicalTrials.gov